Oncologists Reveal Why ALK+ NSCLC Patients Switch Or Discontinue Treatment

We surveyed 25 U.S. medical oncologists to take a closer look at the key drivers of treatment discontinuation or switching in ALK+ NSCLC patients.


Download your copy of the report today to explore the factors that lead to treatment discontinuation, as well as how oncologists rank currently available ALK+ NSCLC treatments, so you can help your brand stand out.